If this is true your doctor should have this implemented in their hospital within the month. To not do so should be a fireable offense of the stroke department head. Heads need to start rolling for the pathetic implementation of new stroke therapies. A
great stroke association would be contacting every stroke hospital president on a monthly basis to make sure the latest is being implemented in their hospital. Anything less is pure incompetence on the part of the stroke associations. Of course your doctor will know of the
recommendation of not using high does of statins to treat cholesterol.
Comparative effects of more versus less aggressive treatment with statins on the long-term outcome of patients with acute ischemic stroke
Abstract
BACKGROUND AND AIMS:
There
are no studies that compared the effects of different intensities of
statin treatment on the long-term outcome of patients with recent
ischemic stroke. We aimed to evaluate these effects.
METHODS:
We
prospectively studied 436 consecutive patients who were discharged
after acute ischemic stroke (39.2% males, age 78.6 ± 6.7 years). Statin
treatment was categorized in equipotent doses of atorvastatin. One year
after discharge, the functional status was assessed with the modified
Rankin scale (mRS). Adverse outcome was defined as mRS between 2 and 6.
The occurrence of ischemic stroke, myocardial infarction and death was
recorded.
RESULT:
Adverse
outcome rates were lower in patients treated with atorvastatin
20 mg/day or more potent doses of statins than in patients treated with
atorvastatin 10 mg/day (63.5, 38.2 and 48.2%, respectively; p = 0.004).
In binary logistic regression analysis, independent predictors of
adverse outcome were the mRS at discharge (relative risk (RR) 2.33, 95%
confidence interval (CI) 1.77-3.07, p < 0.001) whereas more
aggressive treatment with statins independently predicted favorable
outcome (atorvastatin 20 vs. 10 mg/day, RR 0.30, 95% CI 0.11-0.87,
p = 0.026; atorvastatin 40 mg/day or more potent dose of statins vs.
atorvastatin 10 mg/day, RR 1.66, 95% CI 0.62-4.44, p = NS). The
incidence of cardiovascular events and all-cause mortality showed a
trend for being lower in patients treated with atorvastatin 40-80 mg/day
or rosuvastatin 10-40 mg/day than in those treated with less potent
doses of statins.
CONCLUSION:
More
aggressive statin treatment improves the long-term functional outcome
of patients with acute ischemic stroke more than less aggressive
treatment.
No comments:
Post a Comment